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Abstract: Background: The second intron of Mitogen-Activated Protein Kinase Kinase 4 (MAP2K4),
an important hub in the pro-invasive MAPK pathway, harbors miR-744. There is accumulating
evidence that intronic micro-RNAs (miRNAs) are capable of either supporting or restraining
functional pathways of their host genes, thereby creating intricate regulative networks. We thus
hypothesized that miR-744 regulates glioma migration by interacting with its host’s pathways.
Methods: Patients’ tumor specimens were obtained stereotactically. MiR-744 was overexpressed in
U87, T98G, and primary glioblastoma (GBM) cell lines. Cell mobility was studied using migration and
Boyden chamber assays. Protein and mRNA expression was quantified by SDS-PAGE and qRT-PCR.
Interactions of miR-744 and 3’UTRs were analyzed by luciferase reporter assays, and SMAD2/3,
p38, and beta-Catenin activities by TOP/FOPflash reporter gene assays. Results: As compared to
a normal brain, miR-744 levels were dramatically decreased in GBM samples and in primary GBM
cell lines. Astrocytoma WHO grade II/III exhibited intermediate expression levels. Re-expression
of miR-744 in U87, T98G, and primary GBM cell lines induced focal growth and impaired cell
mobility. Luciferase activity of 3’UTR reporter constructs revealed the pro-invasive factors TGFB1
and DVL2 as direct targets of miR-744. Re-expression of miR-744 reduced levels of TGFB1, DVL2,
and the host MAP2K4, and mitigated activity of TGFB1 and DVL2 downstream targets SMAD2/3 and
beta-Catenin. TGFB1 knock-down repressed MAP2K4 expression. Conclusion: MiR-744 acts as an
intrinsic brake on its host. It impedes MAP2K4 functional pathways through simultaneously targeting
SMAD-, beta-Catenin, and MAPK signaling networks, thereby strongly mitigating pro-migratory
effects of MAP2K4. MiR-744 is strongly repressed in glioma, and its re-expression might attenuate
tumor invasiveness.
Keywords: glioblastoma; migration; microRNAs; MAP2K4
1. Introduction
Micro-RNAs (miRNAs) are short RNA molecules with an established role as important epigenetic
regulators of the transcriptome via recognition of base-complementary signals in the 3’ untranslated
regions of target mRNAs [1,2]. Interestingly, the majority of human miRNA genes are located within
non-coding regions of protein-coding genes [3,4]. It also appears that this colocalization leads to
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coregulation in several instances, either through cotranscription and therefore coexpression, or via
shared cis-regulatory elements [5]. Increasing evidence has begun to unravel the shades of a mechanism
bearing an important role in the regulation of central cellular pathways, rather than just being a
biological pendent of an information compression algorithm. However, we are only on the verge of
understanding its impact on health and disease [6,7]. The Mitogen-Activated Protein Kinase (MAPK)
pathway is one of such central signal transduction pathways, regulating a plethora of essential cellular
functions, including proliferation, differentiation, and modulation of gene expression. One of its
members, Mitogen-Activated Protein Kinase Kinase 4 (MAP2K4), is a well-known tumorigenic kinase
with an established role in metastasis, invasion, and cancer progression [8–10]. MAP2K4 in turn hosts
the intronic microRNA hsa-miR-744, located in the second intron of its host. Even though MAP2K4
has long been recognized as a potent proto-oncogene, little is known about its intronic miRNA. Most
importantly, the relationship between MAP2K4 and miR-744 is as yet completely uncharacterized.
Due to the central and established role of MAP2K4 in tumor biology [11,12], we hypothesized miR-744
to be guilty by association, possibly augmenting or antagonizing MAP2K4s tumor-promoting effects.
In the following manuscript, we provide new and unprecedented evidence of a significant role
of miR-744 in the regulation of its host gene MAP2K4 in human glioma. This is accomplished via
controlling both expression and functional aspects of its host gene. We show how miR-744 inhibits
cell migration and invasion, a key characteristic of glioblastoma (GBM), via targeting three essential
cellular pathways. We finally validate our hypothesis in cell line experiments as well as patients´
tissue samples. We believe that our findings shed some more light on the as yet blurry contours of the
mechanisms underlying tumor development through dysregulation of cellular signaling, and portray
miR-744 as a central molecule in the formation of GBM.
2. Results
2.1. miR-744 Is Strongly Repressed in Human Glioma
To identify human tissues in which miR-744 may fulfill important regulatory functions, we used
the intragenic microRNA database miRIAD (http://bmi.ana.med.uni-muenchen.de/miriad/) [4],
and screened for tissues with high expression levels of this miRNA. As depicted in Figure 1A, among
five different tissues deposited in miRIAD (heart, testis, kidney, cerebellum, and brain), human brain
exhibited the highest expression levels of miR-744, which suggests its implication in the maintenance
of homeostatic conditions in the central nervous system. To investigate our initial hypothesis, we next
quantified miR-744 in stereotactically obtained GBM specimens and primary cell lines obtained from
open GBM resections by qRT-PCR, and found a dramatic reduction of miR-744 as compared to normal
brain tissue (Figure 1B; GBM samples: reduction by 90.3% ± 14.7%, primary GBM cell lines: reduction
by 92.7% ± 7.3%; n = 9 for normal brain tissue, n = 21 for GBM samples, n = 8 for primary GBM cell
lines; p < 0.01). Also, we could detect reduced expression of miR-744 in U87 cells, a human GBM cell
line (Figure 1B; reduction by 97.7% ± 6%, n = 9, p < 0.001).
Collectively, this data shows that miR-744 is highly expressed in human brain tissue, whereas it is
almost entirely repressed in GBM.
To assess the expression of miR-744 in human glioma of different grades, we quantified miR-744
in 15 stereotactically obtained WHO II/III tumors by qRT-PCR. As depicted in Figure 1C, we found
miR-744 also to be repressed; however, expression levels were significantly higher as compared to
GBM (48% ± 20%; WHO II/III: n = 15, GBM: n = 21, p = 0.034). It thus appears that miR-744 expression
is inversely correlated with tumor grade and may contribute to increased tumor aggressiveness.
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Figure 1. miR-744 is strongly repressed in glioma. MiR-744 expression was quantified by qRT-PCR. 
U47 served as the endogenous reference. (A) Expression levels of miR-744 in five different tissues. (B) 
Expression of miR-744 in normal brain tissue (NB) (n = 9), glioblastoma (GBM) (n = 21), primary GBM 
cell lines (n = 9), and U87 cells (n = 9), p < 0.001. (C) Expression of miR-744 in WHO grade °II/°III 
glioma (n = 15) compared to GBM (n = 21), p = 0.034. ** p < 0.001; * p < 0.05. 
2.2. Overexpression of miR-744 Reduces Migration of GBM Cells 
It is a frequently occurring phenomenon that tumors down-regulate, or even hamper, the 
expression of genes that are not useful for malignant transformation. Our next aim was to understand 
the reasons for miR-744 downregulation in human GBM, and thus we investigated the biological 
functions of miR-744 in glioma cells. To this end, we transiently re-expressed miR-744 in U87, T98G, 
and primary GBM cell lines by transfection of the respective premiR and assessed the resulting 
phenotype. Surprisingly, we could not detect any alterations of apoptosis or proliferation after 
transfection of miR-744 (data not shown). 2D wound closure assays however, revealed a strong 
impact of miR-744 on cellular migration, which was markedly attenuated in miR-744 transfected cells 
(Figure 2A). To study the long-term effects of miR-744 on cellular migration, we constructed a miR-
744 delivering expression vector, and stably transfected U87 GBM cells (Figure 2D, left panel). As 
shown in Figure 2B, overexpression of miR-744 leads to a decrease in cellular spreading and induces 
focal growth, pointing towards an alteration of cellular mobility. Importantly, 2D migration and 
Boyden Chamber assays revealed a less invasive phenotype (Figure 2C,D, right panel; reduction of 
46% ± 5.8%, n = 4, p = 0.029). Taken together, this data shows that miR-744 inhibits migration of GBM 
cells. 
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s the endogenous reference. (A) Expression l vels of miR-744 in five different tis ues.
(B) Expressi n of miR-744 in normal brain tissue (NB) (n = 9), glioblastoma (GBM) (n = 21), primary
GBM cell li es (n = 9), and U87 cells (n = 9), p < .001. (C) Expre sion of i -74 grade ◦I /◦
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2.2. Overexpression of miR-744 Reduces Migration of GBM Cells
It is a frequently occurring phenomenon that tumors down-regulate, or even hamper,
the expression of genes that are not useful for malignant transformation. Our next aim was to
understand the reasons for miR-744 downregulation in human GBM, and thus we investigated the
biological functions of miR-744 in glioma cells. To this end, we transiently re-expressed miR-744 in
U87, T98G, and primary GBM cell lines by transfection of the respective premiR and assessed the
resulting phenotype. Surprisingly, we could not detect any alterations of apoptosis or proliferation
after transfection of miR-744 (data not shown). 2D wound closure assays however, revealed a strong
impact of miR-744 on cellular migration, which was markedly attenuated in miR-744 transfected cells
(Figure 2A). To study the long-term effects of miR-744 on cellular migration, we constructed a miR-744
delivering expression vector, and stably transfected U87 GBM cells (Figure 2D, left panel). As shown
in Figure 2B, overexpression of miR-744 leads to a decrease in cellular spreading and induces focal
growth, pointing towards an alteration of cellular mobility. Importantly, 2D migration and Boyden
Chamber assays revealed a less invasive phenotype (Figure 2C,D, right panel; reduction of 46% ± 5.8%,
n = 4, p = 0.029). Taken together, this data shows that miR-744 inhibits migration of GBM cells.
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Figure 2. Overexpression of miR-744 induces focal cell growth and inhibits invasion and migration. 
(A) 2D migration assays of transiently miR-744 transfected cells (left panel: U87; middle panel: T98G; 
right panel: primary GBM cell lines) at start and after 24 hours. Lines mark the initially cell-free area. 
A typical example of 3 experiments is shown. (B) Fluorescence microscopy of control and stably miR-
744 overexpressing cells. (C) 2D migration assays of stably transfected cells; depicted are start state 
and after 24 hours of incubation. Lines mark the cell-free area. A typical example of 3 similar 
experiments is shown. (D) Left panel: MiR-744 levels after stable transfection (induction 14.4-fold ± 
6.0, n = 5, p < 0.001). Right panel: Invasion after stable transfection of U87 cells, measured with 
Collagen-coated Boyden Chamber invasion assays (n = 4, p = 0.029). ** p < 0.001; * p < 0.05. 
2.3. TGFB1 and DVL2 are Direct Targets of miR-744, Regulate Migration in GBM Cells, and are Induced in 
Tissue of Human Malignant Glioma  
To identify direct targets of miR-744 possibly accounting for the detected phenotypic alterations, 
we next combined in silico target prediction and pathway analysis to extract mRNAs (a) containing 
miR-744 binding sites in their 3’ untranslated region (3’UTR), and (b) being involved in the regulation 
of cellular mobility. This prompted us to investigate Transforming Growth Factor Beta 1 (TGFB1) and 
Dishevelled2 (DVL2) in detail, as these were the most promising predicted targets of miR-744 with 
respect to a supposed role in GBM migration [13,14]. To test this assumption, we quantified mRNA 
and protein expression levels of TGFB1 and DVL2 in U87 cells stably overexpressing miR-744, and 
indeed detected a marked decrease of TGFB1 and DVL2 mRNA (reduction of 38% ± 5.6% and 33.6% 
± 4.9%, respectively, n = 5, p < 0.05), and protein expression (reduction of 35.6% ± 8.3% and 36.8% ± 
5.3%; Figure 3A, left and middle panels). To provide experimental proof that both genes are bona 
fide targets of miR-744 in GBM, we performed luciferase reporter gene assays on vector constructs 
containing the full-length 3’-UTR of either TGFB1 or DVL2. As shown in Figure 3A (right panel), co-
transfection of miR-744 mimic and reporter constructs diminished luciferase activity by 37% and 47%, 
respectively, compared to miR scrambled control (n = 5, p < 0.05), thereby proving that both genes are 
direct targets of miR-744. Transient knock-down of both TGFB1 and DVL2 by specific siRNAs (knock-
down efficiency: Supplementary Figure S1) reduced the migratory capabilities of GBM cells in 2D 
migration assays (Figure 3B), thereby closing the anticipated functional loop; miR-744 impairs 
migration of human glioma cells by direct targeting of TGFB1 and DVL2. 
Figure 2. Overexpressi f l ll r th and inhibits invasion and migration.
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miR-744 ove xpressing cells. (C) 2D migration assays of stably transfected c lls; depicted are start
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± 6.0, n = 5, p < 0. 01). Right panel: Invasion after stable transfection of U87 cells, measured with
Collagen-coated Boyden ha er i si ss s ( , 0.029). ** p < 0. 01; * p < .05.
2.3. TGFB1 and L2 are irect Targets of i -744, egulate igration in B ells, and are Induced in
Tissue of Human Malignant Glioma
To identify direct targets of miR-744 possibly accounting for the detected phenotypic alterations,
we next combined in silico target prediction and pathway analysis to extract mRNAs (a) containing
miR-744 binding sites in their 3’ untranslated region (3’UTR), and (b) being involved in the regulation
of cellular obility. This prompted us to investigate Transforming Growth Factor Beta 1 (TGFB1)
and Dishevelled2 (DVL2) in detail, as these were the most promising predicted targets of miR-744
with respect to a supposed role in GBM migration [13,14]. To test this assumption, we quantified
mRNA and protein expression levels of TGFB1 and DVL2 in U87 cells stably overexpressing miR-744,
a in eed detected a marked decrease of TGFB1 and DVL2 mRNA (reduction of 38% ± 5.6% and
33.6% ± 4.9%, respectively, n = 5, p < 0.05), and protein expression (reduction of 35.6% ± 8.3% and
36.8 ± 5.3%; Figure 3A, left and middle panels). To provid experimental pr of that both ge es
are bona fide targets of miR-744 in GBM, w performed luciferase reporter ge e assays on ve or
cons ructs containing the full-length 3’-UTR of either TGFB1 or DVL2. As shown in Figure 3A (right
panel), o-transfection of iR-744 mimic and reporter co structs d minished luciferase activity by
37% and 47%, respectively, compared to miR scrambled control (n = 5, p < 0.05), there y proving that
both genes are direct targets of miR-744. Transient knock-down of both TGFB1 and DVL2 by spe ific
siRNAs (knock-down efficie cy: Supplementary Figure S1) reduced the migratory capabilities of GBM
cells in 2D migration assays (Figur 3B), thereby closing the anticipated functional loop; iR-744
i pairs migration of human glioma cells by direct targeting of TGFB1 and DVL2.
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Figure 3. Transforming Growth Factor Beta 1 (TGFB1) and Dishevelled2 (DVL2) are direct targets of 
miR-744, regulate migration, and are induced in GBM and in Astrocytoma °II/°III. (A) Left and middle 
panels: mRNA and protein expression of TGFB1 and DVL2 in U87 cells stably transfected with miR-
744 or empty vector control, respectively (n = 5, p < 0.05). Right panels: TGFB1 and DVL2 3’UTR 
Luciferase Reporter Gene activity after co-transfection of the respective reporter vectors with miR-744 
or with scrambled control, respectively (DVL2: −47% ± 3,2%, TGFB1: −37% ± 2%, n = 5, p < 0.05). All 
Luciferase and mRNA experiments were performed in triplicates. (B) 2D migration assay after 
transient knock-down of DVL2 and TGFB1 in U87 cells. One representative example of 3 experiments 
is shown. (C) Expression of DVL2 and TGFB1 mRNA in Astrocytoma °II/°III biopsies (n = 10, p < 0.05), 
GBM biopsies (DVL: n = 17, p = 0.001; TGFB1: n = 39, p = 0.015), and primary GBM cell lines (n = 8, p < 
0.001), as compared to normal brain tissue (n = 9). ** p < 0.001; * p < 0.05. n.s. = not significant. 
In GBM and Astrocytoma °II/°III specimens, as well as in primary GBM cells, we found 
significantly increased expression levels of DVL2 and TGFB1. These results are in line with the 
detected down-regulation of miR-744 (Figure 3C; DVL2: GBM, induction 3.35-fold ± 0.14, p = 0.002; 
primary GBM cells, induction 5.4-fold ± 0.46, p < 0.001; normal brain tissue (NB), n = 9; GBM, n = 17; 
primary GBM cells, n = 8. TGFB1: GBM, induction 2.19-fold ± 0.09, p = 0.015; primary GBM cells, 
induction 4.33-fold ± 0.69, p < 0.001; NB, n = 9; GBM, n = 39; primary GBM cells, n = 8). Notably, GBM 
exhibited higher levels of TGFB1 and DVL2 as compared to Astrocytoma °II/°III (Figure 3; TGFB1: 
induction 1.5-fold ± 0.36, p = n.s.; DVL2: induction 2.1-fold ± 0.3, p < 0.001; n = 10 for Astrocytoma 
°II/°III). 
Figure 3. Transforming Growth Factor Beta 1 (TGFB1) and Dishevelled2 (DVL2) are direct targets
of miR-744, regulate migration, and are induced in GBM and in Astrocytoma ◦II/◦III. (A) Left and
middle panels: mRNA and protein expression of TGFB1 and DVL2 in U87 cells stably transfected with
miR-744 or empty vector control, respectively (n = 5, p < 0.05). Right panels: TGFB1 and DVL2 3’UTR
Luciferase Reporter Gene activity after co-transfection of the respective reporter vectors with miR-744
or with scrambled control, respectively (DVL2: −47% ± 3,2%, TGFB1: −37% ± 2%, n = 5, p < 0.05).
All Luciferase and mRNA experiments were performed in triplicates. (B) 2D migration assay after
transient knock-down of DVL2 and TGFB1 in U87 cells. One representative example of 3 experiments
is shown. (C) Expression of DVL2 and TGFB1 mRNA in Astrocytoma ◦II/◦III biopsies (n = 10, p < 0.05),
GBM biopsies (DVL: n = 17, p = 0.001; TGFB1: n = 39, p = 0.015), and primary GBM cell lines (n = 8,
p < 0.001), as compared to normal brain tissue (n = 9). ** p < 0.001; * p < 0.05. n.s. = not significant.
In GB and Astrocyto a ◦II/◦III speci ens, as well as in primary GBM cells, we found
significantly increased expression levels of VL2 and T FB1. These results are in line with the
detected do n-regulation of iR-744 (Figure 3C; DVL2: GB , induction 3.35-fold ± 0.14, p = 0.002;
primary GBM cells, induction 5.4-fold ± 0.46, p < 0.001; normal brain tissue (NB), n = 9; GBM, n = 17;
primary GBM cells, n = 8. TGFB1: GBM, induction 2.19-fold ± 0.09, p = 0.015; primary GBM cells,
induction 4.33-fold ± 0.69, p < 0.001; NB, n = 9; GBM, n = 39; primary GBM cells, n = 8). Notably, GBM
exhibited higher levels of TGFB1 and DVL2 as compared to Astrocytoma ◦II/◦III (Figure 3; TGFB1:
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induction 1.5-fold ± 0.36, p = n.s.; DVL2: induction 2.1-fold ± 0.3, p < 0.001; n = 10 for Astrocytoma
◦II/◦III).
Hence, this data indicates that miR-744 puts the brake on the expression of DVL2 and TGFB1,
which both play an important role as promoters of migration in GBM.
2.4. Via Repression of DVL2 and TGFB1, miR-744 Regulates Beta-Catenin and SMAD-Signaling Pathways
We next set out to gain insight into the molecular pathways underlying the observed phenotypic
alterations. TGFB1 is assumed to enhance cellular mobility through SMAD-dependent induction of
pro-invasive factors such as Matrix Metalloproteinases (MMPs) [15,16], while DVL2 represents a central
inducer of beta-Catenin signaling [17]. Both pathways induce epithelial-to-mesenchymal transition
(EMT), and enhance tumor cell migration [14,17]. Consequently, we next assessed the activation status
of SMAD2/3 and beta-Catenin upon overexpression of miR-744, as these transcription factors represent
important downstream effector molecules of TGFB1 and DVL2 [16,18], respectively. As depicted in
Figure 4A, miR-744 overexpression resulted in a marked reduction of the transcriptionally active
forms of SMAD2/3 and beta-Catenin (SMAD2/3: reduction of 52% ± 15.8%; active beta-Catenin:
reduction of 38.6%± 5.7%). In addition, immunohistochemistry showed a significantly weaker staining
for transcriptional active beta-Catenin upon overexpression of miR-744 as compared to controls
(Figure 4B). In line with these results, subsequent analysis of beta-Catenin-mediated transcriptional
activity by Lef/Tcf luciferase reporter gene assay revealed a significantly reduced activity in cells stably
overexpressing miR-744 (Figure 4C; −46.1% ± 10.7%, n = 5, p < 0.01).
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Figure 4. Stable overexpression of miR-744 represses activity of TGFB1 and DVL2 downstream 
effector molecules SMAD- and β-Catenin. Experiments were conducted after stable overexpression 
of miR-744 as compared to empty vector controls. (A) SDS-PAGE of active β-Catenin and 
phosphorylated SMAD 2/3. (B) Immunohistochemistry staining of active β-Catenin. (C) β-Catenin-
dependent transcriptional activity of Lef/Tcf, measured with TOP/FOPFlash Luciferase Reporter 
Gene Assay (n = 4, p = 0.007). * p < 0.05. 
Taken together, our results show that miR-744 via DVL2 and TGFB1 ameliorates invasive 
properties of GBM cells by down-regulation of beta-Catenin and SMAD-signaling. 
2.5. miR-744 Reduces It’s Host Gene MAP2K4 Through TGFB1-Mediated Negative Feedback 
So far, our results have suggested that miR-744 acts as a counterpart of its host gene MAP2K4, 
an enhancer of cancer progression [8,10]. It thus appeared likely that a negative feedback relationship 
between miR and host might exist. To test this assumption, we assessed MAP2K4 expression in U87 
cells stably overexpressing miR-744, and indeed found reduced mRNA and protein levels (Figure 
5A; mRNA: −66.2% ± 7.9%; protein: −56.2% ± 9.6%; n = 5, p < 0.05). Concordantly, miR-744 
i re 4. Stable overexpression of miR-744 represses activity of TGFB1 and DVL2 downstream effector
molecules SMAD- and β-Catenin. Experiments were conducted after stable overexpression of miR-744
as compared to empty vector controls. (A) SDS-PAGE of active β-Catenin and phosphorylated SMAD
2/3. (B) Immunohistochemistry staining of active β-Catenin. (C) β-Catenin-dependent transcriptional
activity of Lef/Tcf, measured with TOP/FOPFlash Luciferase Reporter Gene Assay (n = 4, p = 0.007).
* p < 0.05.
Taken together, our results show that miR-744 via DVL2 and TGFB1 ameliorates invasive
properties of GBM cells by down-regulation of beta-Catenin and SMAD-signaling.
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2.5. miR-744 Reduces It’s Host Gene MAP2K4 Through TGFB1-Mediated Negative Feedback
So far, our results have suggested that miR-744 acts as a counterpart of its host gene MAP2K4,
an enhancer of cancer progression [8,10]. It thus appeared likely that a negative feedback relationship
between miR and host might exist. To test this assumption, we assessed MAP2K4 expression in
U87 cells stably overexpressing miR-744, and indeed found reduced mRNA and protein levels
(Figure 5A; mRNA: −66.2% ± 7.9%; protein: −56.2% ± 9.6%; n = 5, p < 0.05). Concordantly, miR-744
overexpression attenuated activity of MAP2K4s downstream effector p38. As the 3’UTR of MAP2K4
does not contain any putative binding sites of miR-744, the host obviously is not directly targeted.
We thus hypothesized that miR-744 indirectly represses its host by targeting an activator of the host
gene. As TGFB1 is known to activate p38 MAPK, we speculated that TGFB1 might also fulfill a
function as an enhancer of MAP2K4 signaling. Gene-specific knock-down of TGFB1 (Figure 5C, right
panel) significantly decreased MAP2K4 mRNA and protein levels, thereby strongly supporting this
assumption (Figure 5B; −47.7% ± 3.8%, n = 4, p = 0.004). Not unexpectedly, intronic miR-744 was also
significantly affected by TGFB1 knock-down (Figure 5C, left panel; −38.1% ± 9.5%, n = 4, p = 0.015).
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MAP2K4 and miR-744. The latter directly targets TGFB1, which as a negative feedback results in 
concurrent repression of MAP2K4 and miR-744 (Figure 6). These results highlight the close 
regulatory relationship between intronically located miRs and their host genes. 
Figure 5. miR-744 reduces its host gene Mitogen-Activated Protein Kinase Kinase 4 (MAP2K4) through
TGFB1-mediated negative feedback. (A) mRNA expression of MAP2K4 (left panel), and protein
expression of MAP2K4 and its downstream target phospho-p38 MAPK (right panel), after stable
overexpression of miR-744 as compared to empty vector controls (n = 5, p = 0.003). (B) mRNA (left
panel) and protein expression (right panel) of MAP2K4 after knock-down of TGFB1 (n = 5, p = 0.004).
(C) Expression of miR-744 (left panel) and TGFB1 (right panel) after knock-down of TGFB1 (miR-744:
n = 5, p = 0.015; TGFB1: n = 5, p < 0.001). ** p < 0.001; * p < 0.05.
These results sketch a regulatory loop: TGFB1 simultaneously enhances transcription of MAP2K4
and miR-744. The latter directly targets TGFB1, which as a negative feedback results in concurrent
repression of MAP2K4 and miR-744 (Figure 6). These results highlight the close regulatory relationship
between intronically located miRs and their host genes.
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3. Discussion
In recent years, evidence has accumulated that colocalization of intronic miRNA and the host
gene is not a random choice by nature, but rather fulfills important functional tasks within the host
genes’ pathways. Several studies have experimentally proven in different contexts that intronic
miRNAs are capable of either supporting or restraining functional pathways of their host genes,
thereby creating intricate regulative networks [19,20]. As about half of human miRNAs reside in
introns of protein-coding genes, these examples may signify a more general biological principle.
A very recent study however, has suggested low prevalence of functional association between host and
intronic miRNAs in general, but has assumed a key role of this type of regulation in cellular signaling
pathways requiring tight control [21]. To date, experimental evidence supporting this view is scarce.
As an example of potential high interest, we investigated miR-744, located in the second intron of the
tumorigenic kinase MAP2K4, and its impact on it’s host gene’s functional networks.
Expression patterns of miRNAs are highly heterogeneous among cell types, and pronounced
expression levels of a certain miRNA within a specific tissue is likely to reflect functional relevance.
After analysis of different tissues, we found brain tissue to be the most suitable for further analyses,
due to its high miR-744 expression. With respect to the role of MAP2K4 as a driver of malignancy,
we assessed miR-744 expression in human brain tissue, in Astrocytoma WHO grade II/III, and in the
most malignant brain tumor (i.e., GBM). Interestingly, we detected a gradual tumor-grade-dependent
loss of expression, with almost completely lost miR-744 expression levels in GBM. These findings
made us assume that miR-744 is a gatekeeper of oncogenic signaling during the malignization process.
Indeed, stable re-expression of miR-744 in GBM cells resulted in a significantly more benign phenotype,
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with tumor cells growing focally, and migrating less. To uncover the mechanisms underlying these
phenotype changes, we stably overexpressed miR-744 in GBM cells, and evaluated potential miR-744
target genes fulfilling the criteria of (a) being involved in the regulation of cell motility and (b) harboring
potential miR-744 binding sites in their 3’UTRs. We identified and experimentally validated DVL2 and
TGFB1 to be directly regulated by miR-744 in GBM cells. We were further able to show that specific
knock-down of these target genes impaired cellular migration similar to miR-744 overexpression.
In line with these results, we found that down-regulation of miR-744 in human GBM is accompanied
by a marked increase in DVL2 and TGFB1 expression levels, indicating clinical relevance of these
functional networks.
DVL2 and TGFB1 have repeatedly been shown to act as inductors of epithelial-to-mesenchymal
transition (EMT) [13,22,23], one of the hallmarks of cancer progression. During EMT, induction
of Matrix-Metalloproteinases initiates breakdown of the extracellular matrix and reduces cellular
adhesion, which results in enhanced migratory capacity and invasiveness [24,25]. Particularly in GBM,
TGFB1 is one of the most powerful cytokines secreted by the tumor itself. It has repeatedly been
shown that GBM-derived TGFB1 induces EMT via activation of transcription factors of the SMAD
family, thereby increasing migration of GBM cells into the surrounding brain tissue. It thus represents
a hallmark of GBM progression [26–28]. In addition, DVL2, as a key enhancer of beta-Catenin
transcriptional activity, represents another orchestrator of EMT [29–31]. In GBM, the DVL2-beta-catenin
signaling axis has been found to be markedly activated, which significantly contributes to the extremely
invasive nature of these tumors [13,32,33]. To this end, we tested whether inhibition of DVL2 and
TGFB1 by overexpression of miR-744 exerted the supposed impact on the respective downstream
effector molecules, beta-Catenin and SMAD. Based on immunohistochemistry, protein analyses,
and reporter gene assays, our results provided evidence that miR-744 hampers GBM cell migration
via concurrent reduction of SMAD- and beta-Catenin signaling. Thus, downregulation of miR-744
during gliomagenesis may be an effective tumor intrinsic mechanism to support tumor progression by
simultaneously affecting different oncogenic signaling pathways.
This negative impact of miR-744 on tumor cell migration strongly contrasts with the functions
of its host gene, MAP2K4, which has been shown to profoundly enhance cancer cell migration and
metastasis [8,10]. It can thus be concluded that that miR-744 acts as functional antagonist of its host,
thereby keeping a molecular balance. As stable overexpression of miR-744 resulted in significantly
reduced MAP2K4 levels, we assumed that miR-744 may not only control its host functionally, but also
on the level of gene expression through negative feedback. The concept of intronic miRs regulating
their host genes by direct or indirect feedback loops has been experimentally proven in several
different contexts [6,34]. Effects are achieved either directly by targeting of the host’s 3’UTR (first
order negative feedback), or indirectly by targeting an interposed gene that subsequently affects
the host gene’s expression (second order negative feedback). As the 3’UTR of MAP2K4 does not
contain any predicted miR-744 binding sites, we focused on the identification of a second order
negative feedback. In this regard, our finding that stable overexpression of miR-744 attenuated
the activity of MAP2K4’s downstream effector p38 prompted us to come back to TGFB1 as an
important activator of p38 MAPKs [35,36]. Indeed, we could show that gene-specific knock-down of
TGFB1 significantly decreased MAP2K4 expression. Concomitantly, miR-744 levels were decreased,
supporting the notion of a negative feedback loop acting as an “intrinsic transcriptional brake” to
prevent inadequate transcription of MAP2K4. Inhibition of TGFB1 by miR-744 thus fulfills a dual role
in mediating effects of this intronic miRNA on its host MAP2K4: (i) Functional antagonization via
blocking SMAD-signaling, thereby reducing glioma migration and invasion; and (ii) control of the
tumorigenic host’s expression levels.
It is a limitation of the current study that the molecular mechanisms enabling this fundamental
switch remain elusive. However, due to the assumable multi-layered nature of these processes, this
question may be addressed in further research projects.
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4. Materials and Methods
4.1. Bioinformatics
Analysis of potential miR-mRNA interactions was performed using the public databases
TargetScan, PITA, miRIAD, and picTAR. Potential direct interactions were considered probable when 2
or more algorithms returned a positive target prediction. In-silico analysis of miR expression levels
was conducted using the intragenic microRNA database miRIAD (http://bmi.ana.med.uni-muenchen.
de/miriad/). Involvement of target genes in tumor-associated pathways was evaluated using the
KEGG database (www.genome.jp/kegg/pathway.html).
4.2. Human Tissue Samples
Tissue samples (n = 21, GBM; n = 15, WHO II/III Astocytoma; n = 8, primary GBM cell lines; and n
= 9, normal brain) were obtained and processed as described previously [7]. Written informed consent
was given by all patients, and the study protocol was approved by the Institutional Review Board of
the Ludwig-Maximilians University of Munich, Germany (approval number: 216/14). For this study,
only specimens from patients diagnosed with primary GBM, LOH 1p/19q negative, and IDH wild
type were used.
4.3. RNA Extraction and cDNA Synthesis
RNA was extracted using the RNAqueous or miRvana Isolation kit (Ambion, Waltham, MA,
USA), followed by DNAse treatment (Turbo DNAse, Ambion) according to the manufacturer’s
instructions. RNA amount and quality was assessed using a NanoDrop 2000 spectrophotometer
(Thermo Scientific, Waltham, MA, USA). Equal amounts of RNA were transcribed using Oligo-dT
Primers, Random Hexamers (Qiagen, Venlo, Netherlands), dNTPs, RNAse OUT, and Superscript® III
Reverse Transcriptase (Invitrogen, Waltham, MA, USA), following the manufacturer’s instructions.
4.4. Quantitative RT-PCR
Quantitative analysis of mRNA levels was performed on a LightCycler 480 (Roche Diagnostics,
Penzberg, Germany) using 10 ng of cDNA/well. Succinate Dehydrogenase Subunit A (SDHA)
and TATA Box Binding Protein (TBP) were used as reference genes. Quantitative real-time PCR
(qRT-PCR) was conducted using the primers (Metabion, Martinsried, Germany) and UPL Probes
(Roche Diagnostics) provided in Supplementary Table S1. All assays were designed intron spanning.
qRT-PCR conditions comprised initial denaturation for 10 Minutes (95 ◦C), and 50 cycles of 95 ◦C for
10 s, 60 ◦C for 30 s, and 72 ◦C for 1 s. Quantification cycle (Cq) values were calculated employing the
"second derivative maximum" method computed by the LightCycler® software.
4.5. Quantification of miRNA Expression
Mir-744 expression was studied using TaqMan miRNA assays (Applied Biosystems, Waltham,
MA, USA) according to manufacturer’s instructions. MiR-744 and reference gene expression was
measured in technical duplicates. U47 served as an endogenous reference. All patient samples were
calibrated using a sample of normal brain tissue.
4.6. SDS-PAGE
Cells were lysed in cell lysis buffer containing protease and phosphatase inhibitors (Cell Signaling
Technologies, Danvers, MA, USA). Protein concentrations were assessed through BCA assays
(Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.
Forty micrograms of the protein extracts were electrophoresed on 10% SDS-PAGE gels and
electroblotted on PVDF-membranes. Nonspecific binding was blocked with 5% Bovine Serum Albumin
(BSA) in TBS-Tween-20 (TBST) (Sigma, St.Louis, MO, USA). Antibodies for MAP2K4 (Cat. No. 9152),
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TGFB1 (Clone 56E4, Cat. No. 3709), DVL2 (Clone 30D2, Cat. No. 3224), and β-Actin (Clone 13E5,
Cat. No. 4970) (all Cell Signaling Technologies) were diluted in TBST with 1% BSA. β-Actin served
as the loading control. Immunoreactivity was assessed using horseradish peroxidase-labeled goat
anti-mouse or goat anti-rabbit antibodies (Cell Signaling Technologies).
4.7. Cell Culture
U87 and T98G GBM cells were purchased from the American Type Cell Culture Collection
(ATCC). Cells were maintained in DMEM (Gibco) with 10% FCS (Biochrom AG), 2% L-Glutamine, 1%
Penicillin/Streptomycin, 1% MEM NEAA (Invitrogen), and 1% Sodium Pyruvate (PAA). HEK-293
cells (ATCC) were maintained in DMEM with 10% FCS, 2% L-Glutamine, 1% Penicillin/Streptomycin,
and 1% MEM NEAA. Primary GBM cell lines were obtained from patients undergoing open
GBM resection, according to the study protocol mentioned above. Tumor tissue was dissociated
using the Brain Tumor Dissociation Kit P (Miltenyi, Bergisch-Gladbach, Germany) according to
the manufacturer’s instructions. Primary GBM cells were cultivated in MACS Neuro Medium
supplemented with Neuro Brew-21 without Vitamin A (Miltenyi).
4.8. Cloning of Reporter Constructs
The 3’UTRs of TGFB1 and DVL2 were amplified using genomic DNA and primer with XhoI
and NotI, or PmEI and XhoI, restriction sites. Primer sequences are supplied in Supplementary
Table S2. PCR products were cloned into the psiCHECK2 vector (Promega, Mannheim, Germany).
Correct sequences were verified by Sanger sequencing (Eurofins Operon, Ebersberg, Germany).
Plasmids were purified using the Qiaprep Spin Plasmid Miniprep Kit (Qiagen) and the Pure Yield
Plasmid Midiprep System (Promega). DNA concentrations were determined using a NanoDrop 2000
spectrophotometer (Thermo Fisher Scientific).
4.9. Cloning of miRNA Expression Vector
The pre-miR sequence was amplified using genomic DNA and specific primers (sequences
supplied in Supplementary Table S2). The resulting amplicon was cloned into the pmRZs-Green1
vector (Promega).
4.10. Transfections
Transfections were conducted using the NEON electroporation device (Life Technologies,
Waltham, MA, USA). Transient transfection with microRNA precursors (premiR, Thermo Fisher
Scientific) or siRNA (Dharmacon, Lafayette, CO, USA) was carried out at final concentrations of
50 nM (premiR) or 100 nM (siRNA), and 250,000 cells per well. Cells were incubated for 36 h at 37 ◦C
and 5% CO2 in an antibiotics-free medium. Stable transfection was performed using 1 million cells
and 10 µg plasmid/well. After incubation for 12 h in antibiotics-free medium, cells were seeded in
DMEM containing 750 µg/mL Geneticin (Life Technologies). Stable transfection was analyzed by flow
cytometry (Attune, Life Technologies). Monoclonal cell lines were obtained by single-cell picking.
Overexpression of miR-744 was assessed through TaqMan assays. Co-transfection of luciferase reporter
plasmids and premiR™ was carried out using 100,000 HEK-293 cells and 1 µg of Psi-CHECK™2
plasmid. All transfection experiments were performed in triplicate.
4.11. Reporter Gene Assays
After 36 h of incubation, co-transfected cells were harvested, washed twice, and resuspended
in 20µl medium. Luminescence was measured with the MicroLumat Plus (Berthold Technologies,
Bad Wildbad, Germany) using the Dual-Glo Luciferase Assay system (Promega), according to
manufacturer’s instructions. All experiments were performed in triplicate.
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4.12. Migration Assays
70,000 cells/well were seeded in 2-well culture inserts (Ibidi, Martinsried, Germany) and
incubated for 24 h at 37 ◦C with 5% CO2 in a humidified incubator. Inserts were removed, cells
were washed with cell culture media, and pictures were obtained using an inverted microscope (Carl
Zeiss, Jena, Germany). Cells were incubated for 24 h in a cell culture incubator. Pictures were obtained
and cells were fixed with methanol.Invasive properties were studied with the Cytoselect Assay,
Collagen I, Colorimetric Format (Cell Biolabs, San Diego, CA, USA). 100.000 Cells were resuspended
in 250 µL FCS-free media and seeded into the upper compartment of the boyden chamber. DMEM
containing 10% FCS was added to the lower compartment. After incubation for 24 h in a cell culture
incubator, non-invasive cells were removed with cotton swabs, invasive cells were stained, lysed,
and the optical density was determined. Experiments were performed in duplicate.
4.13. Immunohistochemistry
100,000 cells were seeded on glass slides (Falcon) and incubated for 2 days. Cells were washed
with PBS, fixed with ice-cold acetone, and washed with TBST. Endogenous peroxidase was blocked
(1% H2O2, 10 minutes), cells were washed twice with TBST, and incubated in 5% normal goat serum
for 1h. Antibodies were diluted in Antibody Diluent (Cell Signaling Technologies) at a concentration
of 1:800 and incubated at 4 ◦C overnight. Cells were washed twice with TBST and Signal Stain Boost
IHC Detection Reagent was added (Cell Signaling Technologies). After washing with TBST, Signal
Stain DAB substrate was added for 45 s. Thereafter, cells were washed with TBST. Counterstaining
was performed with Haematoxylin (Sigma Aldrich).
4.14. Statistics
All data is presented as the mean ± SEM. p-values were calculated using student’s t-tests.
Statistical analyses were performed using SigmaPlot 12.0 (Systat Software). p-values below 0.05
were considered statistically significant (* p < 0.05; ** p < 0.001).
5. Conclusions
Taken together, we here uncovered a new regulatory circuit consisting of the tumorigenic host
gene MAP2K4 and its intronically located miR-744; miR-744 acts as an intrinsic brake on its host by
counterbalancing both its expression and function. In human glioma, this circuit is disrupted, leading
to an invasion-promoting constellation where miR-744 is almost completely repressed while its host
is induced.
Our data underscores the necessity to gain further profound insights into the networks of intronic
miRNAs and their hosts, which is particularly important with respect to potential clinical approaches.
Counteracting the shortfall of miR-744 in GBM pharmacologically, for example, might be an innovative
clinical direction to pursue.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/11/
400/s1, Table S1: Primer sequences for qRT-PCR; Table S2: Primer sequences for molecular cloning; Figure S1:
Knock-down efficiency after transient transfection of U87 GBM cells with DVL2 or TGFB1 siRNA, as analyzed
by qRT-PCR.
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